prostate cancer

Hormone therapy for prostate cancer causes kidney failure: Study

Friday, July 26, 2013 by: Jonathan Benson, staff writer
Tags: androgen deprivation therapy, prostate cancer, kidney failure

eTrust Pro Certified

Most Viewed Articles
Popular on Facebook
Biologist explains how marijuana causes tumor cells to commit suicide
Companies begin planting microchips under employees' skin
NJ cops bust teenagers shoveling snow without a permit
Chemotherapy kills cancer patients faster than no treatment at all
U2's Bono partners with Monsanto to destroy African agriculture with GMOs
FDA targets Dr. Bronner's Magic Soaps for sharing health benefits of coconut oil
Italian court rules mercury and aluminum in vaccines cause autism: US media continues total blackout of medical truth
Orthorexia Nervosa - New mental disorder aimed at people who insist on eating a clean diet
Whooping cough outbreak at Massachusetts high school affected only vaccinated students
Inuit Elders tell NASA Earth Axis Shifted
Vaccine flu shots still contain 25 micrograms mercury - 100 times the concentration of 'mercury-loaded' fish
Measles outbreak likely caused by vaccinated children, science shows
Baby formula is loaded with GMOs - Avoid these brands
Extreme trauma from male circumcision causes damage to areas of brain
Terminal stage IV lung cancer patient miraculously cured by cannabis oil
Costco stops selling antibiotic laden chicken in response to consumer demand
FDA cracks down Walmart, GNC, other companies selling supplements that do not contain the herbs on the label
McDonald's french fries found to contain Silly Putty ingredient and petroleum chemical

Delicious
(NaturalNews) Men who undergo conventional hormone therapy treatments for prostate cancer could be setting themselves up for another potential health problem later on in life: renal failure. This was the shocking finding of a recent study published in the Journal of the American Medical Association (JAMA), which found that androgen deprivation therapy (ADT), which suppresses testosterone, may lead to a rapid reduction in kidney function, and thus induce kidney failure.

Researchers from McGill University in Canada came to this conclusion after studying the effects of ADT in more than 10,000 men diagnosed with non-metastatic prostate cancer. Though the treatment can sometimes help induce prostate cancer regression in some men, it may also cause a hypogonadal condition that can eventually develop into acute kidney injury (AKI). In a worst-case scenario, ADT can lead to full renal failure, which can ultimately lead to death.

Among the 10,250 men evaluated as part of the study, 232 cases of first-ever AKI admission were identified during post-treatment followup evaluations. Compared to men who had never received ADT, those who did were found to be up to 250 times more likely to develop AKI, a finding that the study's researchers later quantified as a "significant" association between AKI and ADT. From this, the team deduced that ADT directly affects the likelihood of developing AKI.

"To our knowledge, this is the first population-based study to investigate the association between the use of ADT and the risk of AKI in men with prostate cancer," wrote the authors about their findings. "In this study, the use of ADT was associated with an increased risk of AKI, with variations observed with certain types of ADTs. This association remained continuously elevated, with the highest odds ratio observed in the first year of treatment. Overall, these results remained consistent after conducting several sensitivity analyses."

ADT needs to be administered far more discriminately, say experts

The testosterone-inhibiting effects of ADT can also lead to other serious health problems in men including psychological damage, blood disorders, erectile dysfunction, low energy and fatigue, diabetes, heart disease, bone loss, and even permanent endocrine imbalance. In other words, ADT is not something that cancer doctors should administer lightly, especially when prostate cancer symptoms are ambiguous.

"Our study does raise the concern that perhaps we should be more careful in prescribing androgen deprivation therapy in patients who do not have the clear indication of it," said Laurent Azoulay, one of the study's researchers. "It's all about the balance, finding the right population for which the benefits clearly outweigh the risks."

Sources for this article include:

http://www.reuters.com

http://www.oncologynurseadvisor.com

http://www.ctvnews.ca

http://www.cof.org.cn

http://science.naturalnews.com

http://science.naturalnews.com

Join over four million monthly readers. Your privacy is protected. Unsubscribe at any time.
comments powered by Disqus
Take Action: Support NaturalNews.com by linking back to this article from your website

Permalink to this article:

Embed article link: (copy HTML code below):

Reprinting this article:
Non-commercial use OK, cite NaturalNews.com with clickable link.

Follow Natural News on Facebook, Twitter, Google Plus, and Pinterest

Colloidal Silver

Advertise with NaturalNews...

Support NaturalNews Sponsors:

Advertise with NaturalNews...

GET SHOW DETAILS
+ a FREE GIFT

Sign up for the FREE Natural News Email Newsletter

Receive breaking news on GMOs, vaccines, fluoride, radiation protection, natural cures, food safety alerts and interviews with the world's top experts on natural health and more.

Join over 7 million monthly readers of NaturalNews.com, the internet's No. 1 natural health news site. (Source: Alexa.com)

Your email address *

Please enter the code you see above*

No Thanks

Already have it and love it!

Natural News supports and helps fund these organizations:

* Required. Once you click submit, we will send you an email asking you to confirm your free registration. Your privacy is assured and your information is kept confidential. You may unsubscribe at anytime.